NONOF - Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai
2025-10-20 14:20:15 ET
Rani Therapeutics Overview
I'm initiating coverage on Rani Therapeutics Holdings, Inc. ( RANI ) and believe that I should set it at a Buy rating. The reason why I believe that I should do this is because of three major pipeline advancements that could ultimately yield shareholder value. The first most notable program advancement to mention is that this company was able to establish up to a $1.085 billion collaboration deal with Chugai Pharmaceutical. The purpose of this is for Rani to supply its RaniPill technology, and then Chugai is to provide the expertise of antibody development for the targeting of patients with rare and immunological disorders. More about this deal below, but there is another milestone for investors to keep an eye on....
Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai